Iron deficiency anemia
Conditions
Interventions
Carboxymaltose iron group:Carboxymaltose iron
Iron isomaltose group:Iron isomaltose therapy
Ferric sucrose group:Ferric sucrose therapy
Sponsors
Tianjin Medical University General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Because the sample population of this study involved multiple departments, patients in surgical departments (orthopedics, general surgery, gynecological oncology) and internal medicine departments (nephrology) had great differences in disease status, diagnosis and treatment strategy, and application needs of intravenous iron agents. Therefore, the inclusion and exclusion criteria are formulated separately: 1. General surgery, orthopedics, Gynecology (gynecologic tumor) patients: Inclusion criteria: (1) Patients undergoing elective surgery, orthopedics, gynecology (tumor) surgery; (2) Age 18 and above; (3) From January 1, 2024 to December 31, 2024, the patient was admitted to the hospital of the research Center and during the surgical treatment (perioperative period), intravenous use of percarboxyl iron maltose/iron sucrose/iron isommaltose; (4) The application indication of intravenous iron is clear and reasonable. 2. Patients in renal department: Inclusion criteria: (1) The diagnosis is consistent with the "Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia" (2018 Revision), and there is no limit to whether hemodialysis treatment is performed; (2) Age 18 and above; (3) No history of blood transfusion in the past 3 months; (4) From January 1, 2024 to December 31, 2024, he/she was admitted to the research Center hospital and received intravenous application of percarboxyl iron maltose/iron sucrose/iron isommaltose.
Exclusion criteria
Exclusion criteria: 1. General surgery, orthopedics, Gynecology (gynecologic tumor) patients: Exclusion criteria: (1) Patients who received allogeneic blood transfusion before surgery; (2) Patients undergoing emergency surgery due to acute trauma/bone injury; (3) Currently has an infection or other major/life-threatening illness that is difficult to control; (4) Women during pregnancy; (5) Bone marrow hematopoietic dysfunction; (6) Patients with severe hyperthyroidism and hemolytic reaction; (7) Patients with incomplete clinical records or missing follow-up. 2. Patients in renal department: Exclusion criteria: (1) Combined with malignant tumor; (2) Currently has an infection or other major/life-threatening illness that is difficult to control; (3) Women during pregnancy; (4) Bone marrow hematopoietic dysfunction; (5) Patients with severe hyperthyroidism and hemolytic reaction; (6) Patients with incomplete clinical records or missing follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| RBC;Hb;HCT;MCV;MCH;MCHC; | — |
Secondary
| Measure | Time frame |
|---|---|
| SF;SI;TRF;TIBC;TS;IS;Length of stay;Blood transfusion rate and volume;The interval between the onset of anemia again; | — |
Countries
China
Contacts
Public ContactLi Zhengxiang
Tianjin Medical University General Hospital
Outcome results
None listed